Bayer has developed a new gadolinium-based MRI contrast agent named gadoquatrane, which allows for significantly lower doses of gadolinium, reducing it to 0.04 mmol/kg, compared to the standard 0.1 mmol/kg. This advancement is important for patient safety and environmental sustainability as it maintains diagnostic quality while minimizing the amount of gadolinium used. The positive effects are especially relevant for patients requiring frequent imaging, such as those with breast cancer, multiple sclerosis, and various cardiac conditions. Bayer presented findings from the Phase III QUANTI study at ECR 2026, showing that this new agent met all clinical endpoints and demonstrated diagnostic equivalence with existing preparations using up to 60% less gadolinium. Bayer has submitted marketing authorization applications for gadoquatrane in multiple countries, aiming to secure its place as the macrocyclic gadolinium-based contrast agent with the lowest approved dose on the market.
Thu, 19 Mar 2026 05:04:57 GMT | healthcare-in-europe.com